Trader notes, earnings previews, Confluences, weekly digests and roundups — long-form analysis grounded in ORTEX short interest, options flow and analyst data.
Market Commentary — 7990 total
Analysts made their boldest move on SPGI today. The consensus target price jumped to $500.38 from $462.67 — a $37 swing. That's a 8% increase in the average target. The ratings data, street stays firmly bullish with 23…
Fresh filings reveal a wave of insider selling at two well-known US companies, with the biggest exit coming from a chip-equipment giant. Applied Materials CEO Gary Dickerson filed $55.5M in sales last week, with trades…
Short sellers have been busy this week. CoreWeave saw the biggest jump among major names. Its SI % of FF rose to 29.4% — up 5.7 percentage points in just seven days. Bears are clearly skeptical of the AI cloud…
The first big week of the Q2 2026 earnings season starts today. EPAC reports after the close. Tomorrow, PEP leads with its Q2 results. LEVI also reports Tuesday. Analysts have lifted targets on Levi ahead of results,…
Today brings the first confirmed results of the week. EPAC — Enerpac Tool Group — reports Q3 2026 results after the close today. Tomorrow is the busiest day. PEP kicks off with its Q2 2026 pre-recorded earnings call.…
Analysts trimmed targets across several sectors Monday. The most notable action was a downgrade of RJF by the consensus. Raymond James Financial dropped from 9 holds to 8, with a buy count unchanged at zero. The stock…
Insider filings over the past two weeks reveal a split picture. Big sellers dominate the headlines, but a handful of executives are putting their own money to work. CEO Loads Up on $50M Summit Therapeutics Chairman and…
Short sellers turned up the heat on CRWV this week. CoreWeave's short interest jumped to 29.4% of free float — up 5.7 percentage points in seven days. The AI cloud firm, which only went public in March, continues to…
Markets kick off the week with several converging themes: extreme short positions, a wave of insider selling at chip companies, and a busy earnings calendar that starts today. Hertz is the most compressed short in the…
Short sellers and options traders are focusing on two names this week: HTZ and CRWV. Hertz carries a massive 60.8% short interest as a percentage of free float. Availability sits at zero — meaning there are virtually…
Today brings the first mover. EPAC — Enerpac Tool Group — reports Q3 2026 results after the close on Monday. It sets the tone for a busy few days. Tuesday is the headline session. PEP drops its Q2 2026 pre-recorded…
Analyst desks were busy on Monday, with notable moves across financials, technology, and healthcare. The biggest banking call was a downgrade of TFC. Truist Financial was cut from Hold to Sell, with the consensus…
Analysts made sharp moves across sectors on Monday. A bank downgrade, a pharma lift, and oil field services pressure stand out. Truist Financial took the most notable hit. Analysts downgraded the stock, cutting the…
Applied Materials CEO Gary Dickerson filed sales totalling nearly $50M last week. The filings — reported July 1 — show Dickerson sold over 70,000 shares across two days at prices between $700 and $736. AMAT's CTO…
Short sellers ramped up positions in several notable names last week. Hertz Global Holdings leads the pack in terms of sheer movement. SI jumped from 48.9% to 60.8% of free float in just seven days. That's a 12-point…
Vertex Pharmaceuticals grabbed the spotlight Monday. It agreed to buy Crinetics Pharmaceuticals for $85 per share in cash. CRNX stock doubled on the news. Short interest had sat at 13.6% of free float before the deal —…
A blockbuster after-hours deal sent options traders scrambling Monday. Vertex Pharmaceuticals agreed to buy Crinetics Pharmaceuticals for $85 per share in cash. CRNX stock doubled on the news. The deal is a sharp jolt…
The week of July 6 brings a focused but telling roster of corporate results. Three names stand out from the crowd. PEP kicks things off Wednesday evening. PepsiCo's Q2 2026 pre-recorded earnings call lands July 8. The…
HSBC analyst Rajesh Kumar hit Regeneron Pharmaceuticals and Zoetis with sharp target price cuts on Monday, flagging growing pressure across the healthcare space. Regeneron's target dropped to $880 from $990. Zoetis…
Two defence chiefs and an EV founder were buying stock last week. Meanwhile, a top US semiconductor executive was quietly cashing out. ASTS founder and CEO Abel Avellan filed on June 23, disclosing he sold 2.5 million…
